Natco Pharma ties up with Gilead on hepatitis C drugs

Natco will fix its own price for generic versions, will pay royalty on sales

Natco Pharma Limited said on Monday it signed a licensing deal with Gilead Sciences Inc to make and sell generic versions of the US drugmaker's chronic hepatitis C medicines.

Drugs under the deal include sofosbuvir, a combination of ledipasvir and sofosbuvir, and GS-5816, which is in late-stage clinical trials, Natco said in a statement.

Natco will fix its own price for the generic versions, and will pay a royalty on sales to Gilead, the company said.